GleamWall
中文EN

TLPH TALPHERA, INC.

Pharmaceutical Preparations · Nasdaq · SEC CIK 1427925 · Fiscal year ends 12/31

Financial factors as of 2026-06-30 (2026Q2), TTM = sum of the last four quarters

Growth

TTM revenue YoY-96.3%
TTM net income YoY-33.4%
TTM EPS YoY—
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin-1,474,700.0%
Net margin-1,507,600.0%
FCF margin—
EBITDA margin—

Returns

ROE-143.4%
ROA-69.6%
ROIC (approx.)-172.6%
Asset turnover0.00x

Leverage & solvency

Liabilities / assets46.3%
Debt / equity0.00x
Current ratio4.29x
Interest coverage—

Cash quality & payout

Operating cash flow / net income0.81x
Accruals ratio-13.0%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item 2026Q32026-09-302026Q22026-06-302026Q12026-03-312025Q4*2025-12-312025Q32025-09-302025Q22025-06-302025Q12025-03-312024Q4*2024-12-31
Income statement
Revenue$0$0$0$0$1,000$0$27,000$0
R&D expense$2.19M$1.69M$1.65M$1.56M$1.80M$1.50M$1.17M$1.32M
SG&A expense$1.95M$2.23M$2.30M$1.89M$1.62M$2.19M$1.77M$1.67M
Operating income-$4.14M-$3.92M-$3.95M-$3.45M-$3.42M-$3.69M-$2.92M-$3.00M
Interest expense———————$0
Income tax———————$0
Net income-$4.02M-$4.31M-$2.56M-$3.77M-$4.44M-$3.49M-$2.59M-$1.87M
EBITDA———————-$3.00M
EPS (basic)-0.05-0.06-0.04—-0.11-0.10-0.10—
EPS (diluted)——————-0.10—
Balance sheet
Cash & equivalents$10.66M$742,000$3.82M$5.89M$3.46M$6.79M$5.39M$8.86M
Short-term investments$3.50M$16.33M$17.29M$14.49M$17.83M——$0
Current assets$14.76M$17.99M$21.34M$20.90M$21.92M$7.70M$6.18M$9.42M
Intangibles$8.82M$8.82M$8.82M$8.82M$8.82M$8.82M$8.82M$8.82M
Total assets$23.57M$26.81M$30.16M$29.72M$30.74M$16.52M$14.99M$18.24M
Current liabilities$4.63M$4.19M$4.03M$3.81M$3.21M$2.63M$1.99M$2.65M
Total liabilities$12.86M$12.40M$11.68M$12.68M$11.56M$9.89M$9.40M$10.23M
Shareholders' equity$10.71M$14.41M$18.48M$17.04M$19.18M$6.63M$5.60M$8.00M
Shares outstanding51.95M51.91M50.05M49.33M45.59M20.52M17.10M17.03M
Cash flow statement
Operating cash flow-$3.03M-$3.92M-$3.40M-$2.44M-$2.51M-$2.95M-$3.47M-$2.25M
Capital expenditure———————$0
Free cash flow———————-$2.25M
Investing cash flow$12.92M$1.10M-$2.71M$3.47M-$17.82M$0$0$0
Financing cash flow$32,000-$261,000$4.04M$1.40M$16.99M$4.35M-$5,000$0
Depreciation & amortization———————$0
Stock-based compensation$292,000$243,000$214,000$185,000$152,000$166,000$196,000$230,000

Free plan shows the latest 8 periods; Pro shows all 66 🔒

· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.